Pfizer Inc. (NYSE:PFE) Receives $32.14 Average Price Target from Analysts

Pfizer Inc. (NYSE:PFE) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $32.15.

PFE has been the subject of several analyst reports. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Founders Financial Securities LLC lifted its position in Pfizer by 18.5% during the second quarter. Founders Financial Securities LLC now owns 16,414 shares of the biopharmaceutical company’s stock valued at $459,000 after acquiring an additional 2,558 shares during the last quarter. Cozad Asset Management Inc. lifted its holdings in shares of Pfizer by 1.3% during the 2nd quarter. Cozad Asset Management Inc. now owns 44,417 shares of the biopharmaceutical company’s stock valued at $1,243,000 after purchasing an additional 580 shares during the last quarter. Foundations Investment Advisors LLC boosted its position in shares of Pfizer by 2.1% in the 2nd quarter. Foundations Investment Advisors LLC now owns 96,169 shares of the biopharmaceutical company’s stock worth $2,691,000 after purchasing an additional 1,937 shares in the last quarter. Hodges Capital Management Inc. grew its stake in Pfizer by 12.4% during the 2nd quarter. Hodges Capital Management Inc. now owns 13,631 shares of the biopharmaceutical company’s stock worth $381,000 after buying an additional 1,504 shares during the last quarter. Finally, Larson Financial Group LLC increased its position in Pfizer by 76.0% during the 2nd quarter. Larson Financial Group LLC now owns 59,427 shares of the biopharmaceutical company’s stock valued at $1,663,000 after buying an additional 25,658 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.1 %

PFE stock opened at $26.59 on Friday. The firm has a market cap of $150.69 billion, a PE ratio of 35.93, a price-to-earnings-growth ratio of 0.63 and a beta of 0.65. The firm has a fifty day moving average price of $26.33 and a 200 day moving average price of $28.07. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the firm posted ($0.17) EPS. The business’s quarterly revenue was up 31.2% on a year-over-year basis. Sell-side analysts anticipate that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.47%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.